Chemical constituents from Callicarpa nudiflora and their cytotoxic activities / 中国中药杂志

The chemical consitituents from cytotoxic fraction of the Callicarpa nudiflora extract were isolated and purified by a combination of HP-20 macroporous resin, silica gel and Sephadex LH-20 column chromatographies. The structures were elucidated on the basis of the spectroscopic data and comparison of their spectroscopic data with reported data. The cytotoxicity was evaluated by the MTT assay. The 50% and 70% EtOH elutions of EtOH-extract showed significant cytotoxic activities, leading to the isolation of twelve compounds, which were identified as luteoloside(1), lutedin-4'-O-β-D-glucoside(2), 6-hydroxyluteolin-7-O-β-glucoside(3), lutedin-7-O-neohesperidoside(4), rhoifolin (5), luteolin-7, 4'-di-O-glucoside (6), forsythoside B (7), acteoside (8), alyssonoside (9), catalpol(10), nudifloside(11), and leonuride(12). Compounds 3-6, 10 and 12 were isolated from this genus for the first time, and compound 9 was isolated from this plant for the first time. The cytotoxicity assay demonstrated that flavonoids 1-6, in various concentrations, showed monolithic proliferation inhibitory activities against Hela, A549 and MCF-7 cell lines. Compounds 3, 5 and iridoid glycoside 11 possessed higher cytotoxicacivities. In short, flavonoids are the main components of cytotoxic extract from C. nudiflora, while phenylethanoid glycosides are the predominant ingredient but inactive to cancer cell lines. In addition, the minor iridoid glycoside expressed weak cytotoxic activity.

Prognosis analysis of 216 cases of gastrointestinal stromal tumor / 中华胃肠外科杂志

<p><b>OBJECTIVE</b>To analyze the impact of location of gastrointestinal stromal tumor(GIST) on the survival, and the influence of surgical treatment and imatinib therapy on survival.</p><p><b>METHODS</b>The clinical data of 216 patients with GIST who were admitted to the People's Liberation Army Hospital from January 2004 to December 2010 were analyzed retrospectively.</p><p><b>RESULTS</b>All the patients were followed up with a median time of 22 months(1 to 83 months). The 1-, 3-, and 5-year survival rates were 93%, 75% and 30%. The survival rates of 5-year with GIST located in the stomach (103 cases), the small intestine (45 cases) and gastrointestinal outside(41 cases) were 93%, 75%, and 30%, respectively, and the differences were statistically significant(P<0.05). There were no deaths in patients with GIST located in duodenum(18 cases) and rectum(9 cases). The 5-years survival rates of GIST in the groups of complete excision combined with imatinib, complete resection without imatinib, incomplete resection combined with imatinib, incomplete resection without imatinib were 100%, 98%, 49% and 14%, respectively, and the differences were statistically significant(P<0.05).</p><p><b>CONCLUSIONS</b>GISTs in different parts of gastrointestinal tract have different survival rates. Radical resection and imatinib can improve the survival rates of patients with GIST.</p>